PharmaCyte Biotech, Inc.
NCM: PMCBLive Quote
📈 ZcoreAI Score
Our AI model analyzes PharmaCyte Biotech, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PMCB Z-Score →About PharmaCyte Biotech, Inc.
Healthcare
Biotechnology
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
📊 Fundamental Analysis
PharmaCyte Biotech, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -8.2%, which indicates that capital utilization is currently under pressure.
At a current price of $0.65, PMCB currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.63 - $1.51).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$7.01M
Trailing P/E
--
Forward P/E
-1.72
Beta (5Y)
0.41
52W High
$1.51
52W Low
$0.63
Avg Volume
185K
Day High
Day Low